MiniMed Group’s first-quarter net sales rose 16.6% as reported and 15.8% organically to $843 million, with U.S. growth accelerating and international sales continuing to expand. The company raised fiscal 2027 organic Revenue growth guidance to approximately 10.5%, while maintaining adjusted EBITDA Margin guidance of approximately 16%.

Key Highlights

  • MiniMed submitted its Fit patch pump to the U.S. FDA ahead of its fall target.
  • Worldwide net sales reached $843 million, growing 16.6% as reported and 15.8% organically.
  • Fiscal 2027 organic revenue growth guidance rose to approximately 10.5%, while adjusted EBITDA margin guidance remained approximately 16%.

Geographic Sales

The quarter ended July 31, 2026. International net sales increased 18.1% as reported and 16.9% organically. U.S. net sales rose 13.1% on both reported and organic bases.

Revenue Categories

The Other category primarily includes smart insulin pens and services. The company reported basic and Diluted Earnings per Share of $0.00 for the quarter.

MiniMed (NASDAQ: MMED) Flex Drives U.S. Growth

The release also identified an August 17 start for the U.S. launch of MiniMed (NASDAQ: MMED) Flex with Instinct. MiniMed said the product’s U.S. launch activity was contributing to new-patient and account growth.

Organic Revenue Guidance Raised

The company reaffirmed its adjusted EBITDA margin outlook at approximately 16% and raised organic revenue growth guidance to approximately 10.5%. Fiscal 2027 ends April 30, 2027.

Pipeline Sets Product Milestones

A full U.S. launch of MiniMed Fit is expected in Summer 2027. MiniMed Flex received the CE Mark ahead of its calendar 2026 year-end target, with commercial launch expected in November. The Vivera fully closed-loop algorithm’s U.S. key trial for Type 1 and Type 2 diabetes completed enrollment and remains on track for a second-half calendar 2027 U.S. launch. The next-generation MiniMed extended-wear sensor received U.S. investigational device exemption approval. First enrollment in its key trial is expected this fall.

Peers Moving on This News